Structure Therapeutics (NASDAQ:GPCR) Shares Down 6.1% – Here’s Why

Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR)’s share price dropped 6.1% during trading on Tuesday. The company traded as low as $33.04 and last traded at $32.9330. Approximately 497,334 shares changed hands during mid-day trading, a decline of 46% from the average daily volume of 920,710 shares. The stock had previously closed at $35.06.

Analyst Ratings Changes

Several brokerages have recently weighed in on GPCR. Citizens Jmp reaffirmed a “market outperform” rating and set a $110.00 target price on shares of Structure Therapeutics in a research note on Wednesday, September 9th. HC Wainwright reissued a “buy” rating on shares of Structure Therapeutics in a report on Wednesday, September 9th. Canaccord Genuity Group set a $111.00 price objective on shares of Structure Therapeutics in a research report on Friday, August 7th. Wall Street Zen raised shares of Structure Therapeutics from a “strong sell” rating to a “sell” rating in a report on Monday, August 17th. Finally, Weiss Ratings lowered shares of Structure Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday, September 18th. Two analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, one has assigned a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $110.91.

Structure Therapeutics Price Performance

The stock has a market capitalization of $2.14 billion, a PE ratio of -30.74 and a beta of -1.45. The company’s 50 day moving average price is $45.54 and its two-hundred day moving average price is $46.09.

Structure Therapeutics (NASDAQ:GPCR) last released its earnings results on Thursday, August 6th. The company reported ($0.49) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.10). Analysts forecast that Structure Therapeutics Inc. Sponsored ADR will post -1.87 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of GPCR. Orbimed Advisors LLC increased its position in Structure Therapeutics by 27.0% during the first quarter. Orbimed Advisors LLC now owns 1,475,403 shares of the company’s stock worth $71,114,000 after purchasing an additional 313,600 shares during the last quarter. Handelsbanken Fonder AB acquired a new position in Structure Therapeutics in the 2nd quarter valued at about $1,041,000. Squarepoint Ops LLC grew its stake in shares of Structure Therapeutics by 454.5% in the 2nd quarter. Squarepoint Ops LLC now owns 125,575 shares of the company’s stock valued at $6,740,000 after buying an additional 102,929 shares during the period. SEB Asset Management AB purchased a new stake in shares of Structure Therapeutics in the 1st quarter valued at approximately $11,811,000. Finally, Wellington Management Group LLP increased its holdings in shares of Structure Therapeutics by 1.6% during the 2nd quarter. Wellington Management Group LLP now owns 7,379,433 shares of the company’s stock worth $396,054,000 after buying an additional 119,146 shares during the last quarter. Institutional investors and hedge funds own 91.78% of the company’s stock.

About Structure Therapeutics

Structure Therapeutics Inc is a clinical-stage biopharmaceutical company developing oral small-molecule medicines for chronic metabolic and cardiopulmonary diseases. The company uses structure-based drug discovery and related technologies to identify therapies intended to address conditions with significant unmet medical needs.

Its lead product candidate is GSBR-1290, an investigational oral small-molecule agonist of the glucagon-like peptide-1 (GLP-1) receptor being developed for obesity and type 2 diabetes.